The goal of this proof-of-concept clinical trial is to evaluate the initial safety, feasibility, and tolerability of the orexin mixed antagonist suvorexant in …

Suicide RiskMajor Depressive Disorder (MDD)

~Estimated

~$10 – $7,500

Marianne GoodmanNCT06854224

Phase 2

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SPN-821 as an Adjunctive Therapy in Adults With Major Depressive Disorder

This study will evaluate the efficacy and safety of SPN-821 in adults with major depressive disorder

Major Depressive Disorder (MDD)

~Estimated

~$10 – $8,750

Supernus Pharmaceuticals, Inc.NCT07226661

Observational

A Randomized, Double Blind Sham Controlled Clinical Trial to Evaluate the Efficacy of Electrical Vestibular Nerve Stimulation (VeNS), Compared to a Sham Control for Treatment of Major Depressive Disorder (MDD) - Modius Mood Study

Trial title: A Randomized, Double Blind Sham Controlled Clinical Trial to Evaluate the Efficacy of Electrical Vestibular Nerve Stimulation (VeNS), Compared to …

Major Depressive Disorder \(MDDDepressive Disorder, Major

~Estimated

~$10 – $8,750

Neurovalens Ltd.NCT06470035

Phase 4

Mechanistic Clinical Trial Evaluating the Role of the Metabotropic Glutamate Receptor Subtype 5 (mGluR5) in the Antidepressant Mechanism of Cognitive Behavioral Therapy for Insomnia (CBT-I)

This is mechanistic clinical trial that evaluates the role of one of the glutamate receptors (mGluR5) in cognitive behavioral therapy for insomnia (CBT-I) as a…

Major Depressive Disorder (MDD)

~Estimated

~$10 – $6,250

Stony Brook UniversityNCT07076342

← PreviousPage 4 of 4Next →